vonoprazan相关的显微镜下结肠炎和发病后继续使用:一项使用日本药物警戒数据库的研究。

IF 1.8 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
In vivo Pub Date : 2025-07-01 DOI:10.21873/invivo.14034
Kota Nakanishi, Yuichi Uwai, Tomohiro Nabekura
{"title":"vonoprazan相关的显微镜下结肠炎和发病后继续使用:一项使用日本药物警戒数据库的研究。","authors":"Kota Nakanishi, Yuichi Uwai, Tomohiro Nabekura","doi":"10.21873/invivo.14034","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>Microscopic colitis is a known side-effect of proton pump inhibitors, but its association with the potassium-competitive acid blocker vonoprazan remains unclear. This study investigated this relationship, including the continued administration of vonoprazan after colitis onset.</p><p><strong>Patients and methods: </strong>Data from the first quarter of 2004 until the first quarter of 2024 in the Japanese Adverse Drug Event Report (JADER) database were analyzed. The reporting odds ratio (ROR) with its 95% confidence interval (CI) was calculated, and logistic regression analyses were performed. The proportion of patients with continued administration after onset was compared using Fisher's exact test with Bonferroni correction, and the administration duration was analyzed using the Steel-Dwass test.</p><p><strong>Results: </strong>Among 1,523,914 adverse drug event reports from 921,160 cases, 751 reports of microscopic colitis were identified. Lansoprazole was the suspected cause in 481 reports (ROR=362, 95% CI=311-421), whereas vonoprazan appeared in 55 reports (ROR=33.5, 95% CI=25.4-44.1). Univariate and multivariate analyses yielded adjusted ORs of 2.56 (95% CI=2.23-2.93) and 2.87 (95% CI=2.48-3.31), respectively, for the association between vonoprazan and microscopic colitis. The time to onset of microscopic colitis in vonoprazan users ranged from 7 to 731 days (median=31 days). The proportion of reports in which lansoprazole and vonoprazan were continued after microscopic colitis onset was higher than that of vonoprazan continuation after drug eruption (<i>i.e</i>. adverse cutaneous reactions). The duration of continued administration after microscopic colitis onset was longer than that after drug eruption.</p><p><strong>Conclusion: </strong>Using the JADER database, this study identified a safety signal for microscopic colitis associated with vonoprazan which is not listed in its package insert. Patients might continue vonoprazan after the onset of microscopic colitis. Although the database relies on spontaneous reporting, these findings warrant further investigation.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2363-2370"},"PeriodicalIF":1.8000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223615/pdf/","citationCount":"0","resultStr":"{\"title\":\"Vonoprazan-associated Microscopic Colitis and Continued Use After Onset: A Study Using a Japanese Pharmacovigilance Database.\",\"authors\":\"Kota Nakanishi, Yuichi Uwai, Tomohiro Nabekura\",\"doi\":\"10.21873/invivo.14034\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background/aim: </strong>Microscopic colitis is a known side-effect of proton pump inhibitors, but its association with the potassium-competitive acid blocker vonoprazan remains unclear. This study investigated this relationship, including the continued administration of vonoprazan after colitis onset.</p><p><strong>Patients and methods: </strong>Data from the first quarter of 2004 until the first quarter of 2024 in the Japanese Adverse Drug Event Report (JADER) database were analyzed. The reporting odds ratio (ROR) with its 95% confidence interval (CI) was calculated, and logistic regression analyses were performed. The proportion of patients with continued administration after onset was compared using Fisher's exact test with Bonferroni correction, and the administration duration was analyzed using the Steel-Dwass test.</p><p><strong>Results: </strong>Among 1,523,914 adverse drug event reports from 921,160 cases, 751 reports of microscopic colitis were identified. Lansoprazole was the suspected cause in 481 reports (ROR=362, 95% CI=311-421), whereas vonoprazan appeared in 55 reports (ROR=33.5, 95% CI=25.4-44.1). Univariate and multivariate analyses yielded adjusted ORs of 2.56 (95% CI=2.23-2.93) and 2.87 (95% CI=2.48-3.31), respectively, for the association between vonoprazan and microscopic colitis. The time to onset of microscopic colitis in vonoprazan users ranged from 7 to 731 days (median=31 days). The proportion of reports in which lansoprazole and vonoprazan were continued after microscopic colitis onset was higher than that of vonoprazan continuation after drug eruption (<i>i.e</i>. adverse cutaneous reactions). The duration of continued administration after microscopic colitis onset was longer than that after drug eruption.</p><p><strong>Conclusion: </strong>Using the JADER database, this study identified a safety signal for microscopic colitis associated with vonoprazan which is not listed in its package insert. Patients might continue vonoprazan after the onset of microscopic colitis. Although the database relies on spontaneous reporting, these findings warrant further investigation.</p>\",\"PeriodicalId\":13364,\"journal\":{\"name\":\"In vivo\",\"volume\":\"39 4\",\"pages\":\"2363-2370\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223615/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"In vivo\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21873/invivo.14034\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"In vivo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/invivo.14034","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

背景/目的:显微镜下结肠炎是质子泵抑制剂的一种已知副作用,但其与钾竞争酸阻滞剂vonoprazan的关系尚不清楚。本研究调查了这种关系,包括结肠炎发作后继续服用vonoprazan。患者和方法:分析日本药品不良事件报告(JADER)数据库中2004年第一季度至2024年第一季度的数据。计算报告优势比(ROR)及其95%可信区间(CI),并进行logistic回归分析。发病后继续给药的患者比例采用Fisher精确检验结合Bonferroni校正,给药时间采用Steel-Dwass检验分析。结果:在9211,160例报告的1,523,914例不良事件中,发现显微镜下结肠炎报告751例。481例报告中怀疑是兰索拉唑引起的(ROR=362, 95% CI=311-421),而55例报告中怀疑是伏诺哌赞引起的(ROR=33.5, 95% CI=25.4-44.1)。单因素和多因素分析显示,vonoprazan与显微镜下结肠炎的相关性调整后的or分别为2.56 (95% CI=2.23-2.93)和2.87 (95% CI=2.48-3.31)。vonoprazan使用者发生显微镜下结肠炎的时间为7至731天(中位=31天)。显微镜下结肠炎发病后继续使用兰索拉唑和伏诺帕赞的报告比例高于药物出疹(即皮肤不良反应)后继续使用伏诺帕赞的报告比例。显微镜下结肠炎发病后持续给药时间比药疹后持续给药时间长。结论:使用JADER数据库,本研究确定了vonoprazan相关显微镜下结肠炎的安全信号,该信号未在其说明书中列出。患者可能在显微镜下结肠炎发病后继续使用vonoprazan。尽管该数据库依赖于自发报告,但这些发现值得进一步调查。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Vonoprazan-associated Microscopic Colitis and Continued Use After Onset: A Study Using a Japanese Pharmacovigilance Database.

Background/aim: Microscopic colitis is a known side-effect of proton pump inhibitors, but its association with the potassium-competitive acid blocker vonoprazan remains unclear. This study investigated this relationship, including the continued administration of vonoprazan after colitis onset.

Patients and methods: Data from the first quarter of 2004 until the first quarter of 2024 in the Japanese Adverse Drug Event Report (JADER) database were analyzed. The reporting odds ratio (ROR) with its 95% confidence interval (CI) was calculated, and logistic regression analyses were performed. The proportion of patients with continued administration after onset was compared using Fisher's exact test with Bonferroni correction, and the administration duration was analyzed using the Steel-Dwass test.

Results: Among 1,523,914 adverse drug event reports from 921,160 cases, 751 reports of microscopic colitis were identified. Lansoprazole was the suspected cause in 481 reports (ROR=362, 95% CI=311-421), whereas vonoprazan appeared in 55 reports (ROR=33.5, 95% CI=25.4-44.1). Univariate and multivariate analyses yielded adjusted ORs of 2.56 (95% CI=2.23-2.93) and 2.87 (95% CI=2.48-3.31), respectively, for the association between vonoprazan and microscopic colitis. The time to onset of microscopic colitis in vonoprazan users ranged from 7 to 731 days (median=31 days). The proportion of reports in which lansoprazole and vonoprazan were continued after microscopic colitis onset was higher than that of vonoprazan continuation after drug eruption (i.e. adverse cutaneous reactions). The duration of continued administration after microscopic colitis onset was longer than that after drug eruption.

Conclusion: Using the JADER database, this study identified a safety signal for microscopic colitis associated with vonoprazan which is not listed in its package insert. Patients might continue vonoprazan after the onset of microscopic colitis. Although the database relies on spontaneous reporting, these findings warrant further investigation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
In vivo
In vivo 医学-医学:研究与实验
CiteScore
4.20
自引率
4.30%
发文量
330
审稿时长
3-8 weeks
期刊介绍: IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management. The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信